Pramipexole 0.125 mg tablets

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Parkinson DiseaseRestless Legs Syndrome

Phase 2

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

CompletedNCT00152997

Boehringer IngelheimRestless Legs Syndrome

Start: 2004-08-31Updated: 2013-10-31

Phase 3

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

CompletedNCT00274131

Boehringer IngelheimParkinson Disease

Start: 1998-12-31End: 2004-02-29Target: 170Updated: 2012-05-21